Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement, according to a notification received from Nasdaq on January 30, 2024. The company had previously been warned on August 8, 2023, that its common stock had been trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq's Listing Rule 5550(a)(2). In response, Avalo Therapeutics executed a reverse stock split on December 28, 2023, which resulted in the stock price remaining above $1.00 since December 29, 2023. Despite regaining compliance, Nasdaq has placed the company under a one-year mandatory panel monitor starting from January 30, 2024. Should Avalo Therapeutics fall below the bid price requirement again within this period, it will not be allowed to submit a compliance plan and could face delisting without the possibility of an extension or cure period. The company would then have the right to request a hearing with a Nasdaq panel to address the issue.
Avalo Therapeutics, Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement, according to a notification received from Nasdaq on January 30, 2024. The company had previously been warned on August 8, 2023, that its common stock had been trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq's Listing Rule 5550(a)(2). In response, Avalo Therapeutics executed a reverse stock split on December 28, 2023, which resulted in the stock price remaining above $1.00 since December 29, 2023. Despite regaining compliance, Nasdaq has placed the company under a one-year mandatory panel monitor starting from January 30, 2024. Should Avalo Therapeutics fall below the bid price requirement again within this period, it will not be allowed to submit a compliance plan and could face delisting without the possibility of an extension or cure period. The company would then have the right to request a hearing with a Nasdaq panel to address the issue.
根據納斯達克於2024年1月30日收到的通知，Avalo Therapeutics, Inc.已成功恢復對納斯達克資本市場的最低出價要求的遵守。該公司此前曾在2023年8月8日受到警告，其普通股連續30個工作日的交易價格低於1.00美元的最低出價，違反了納斯達克的上市規則5550（a）（2）。作爲回應，Avalo Therapeutics於2023年12月28日進行了反向股票拆分，導致股價自2023年12月29日以來一直保持在1.00美元以上。儘管恢復了合規性，但納斯達克已從2024年1月30日起將該公司置於爲期一年的強制性小組監督之下。如果Avalo Therapeutics在這段時間內再次跌破出價要求，它將不允許提交合規計劃，並且可能在沒有延期或治癒期的情況下面臨退市。然後，該公司將有權要求與納斯達克小組舉行聽證會以解決該問題。
根據納斯達克於2024年1月30日收到的通知，Avalo Therapeutics, Inc.已成功恢復對納斯達克資本市場的最低出價要求的遵守。該公司此前曾在2023年8月8日受到警告，其普通股連續30個工作日的交易價格低於1.00美元的最低出價，違反了納斯達克的上市規則5550（a）（2）。作爲回應，Avalo Therapeutics於2023年12月28日進行了反向股票拆分，導致股價自2023年12月29日以來一直保持在1.00美元以上。儘管恢復了合規性，但納斯達克已從2024年1月30日起將該公司置於爲期一年的強制性小組監督之下。如果Avalo Therapeutics在這段時間內再次跌破出價要求，它將不允許提交合規計劃，並且可能在沒有延期或治癒期的情況下面臨退市。然後，該公司將有權要求與納斯達克小組舉行聽證會以解決該問題。
有用
沒用